Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer.

ABSTRACT:

Purpose

Chemotherapeutic adjuvants, such as oxaliplatin (OXA) and 5-fluorouracil (5-FU), that enhance the immune system, are being assessed as strategies to improve durable response rates when used in combination with immune checkpoint inhibitor (ICI) monotherapy in cancer patients. In this study, we explored granzyme B (GZB), released by tumor-associated immune cells, as a PET imaging-based stratification marker for successful combination therapy using a fluorine-18 (¹⁸F)-labelled GZB peptide ([¹⁸F]AlF-mNOTA-GZP).

Methods

Using the immunocompetent CT26 syngeneic mouse model of colon cancer, we assessed the potential for [¹⁸F]AlF-mNOTA-GZP to stratify OXA/5-FU and ICI combination therapy response via GZB PET. In vivo tumor uptake of [^18<

SUBMITTER: Goggi JL 

PROVIDER: S-EPMC8410722 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature